Figure 6.

c-myb^hyper MDS-like zebrafish respond to chemotherapy. (a–g) Drug treatments in embryos. 1 dpf siblings (left panels) and c-myb^hyper (right panels) larvae treated with phosphate-buffered saline control (a) and cytarabine (b) for 5 days and stained with SB at 6 dpf. 1 dpf larvae treated with dimethylsulfoxide (DMSO) control (c), flavopiridol (d) and quizartinib (e) for 6 days and stained with SB at 7 dpf. (f) Average numbers of SB⁺ cells per larva with drug treatment (t-test, sibling and c-myb^hyper, n =14 and n =10, respectively; mean ±s.d.; *P<0.05, **P<0.01). (g) Relative expression of c-myb gene in siblings (blue bar) or c-myb^hyper fish (red bar) treated with flavopiridol or quizartinib were examined by qPCR. (t-test, n =30; mean ±s.d.; *P<0.05, **P<0.01). (h) Drug treatments in adult fish. Blood cell counts of 1-year siblings and c-myb^hyper KM after intraperitoneal injection with flavopiridol (30 mg/kg/day or 130 mg/kg once daily for 4 days) or phosphate-buffered saline (t-test, n =10; mean ±s.d.; *P<0.05, **P<0.01). (i) Relative expression of c-myb gene in siblings (blue bar) or c-myb^hyper adult KM (red bar) treated with flavopiridol was examined by qPCR. (t-test, n =30; mean ±s.d.; *P<0.05, **P<0.01).